- Home
- ROIC vs TARS Comparison
ROIC vs TARS Comparison
Compare ROIC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIC
- TARS
- Stock Information
- Founded
- ROIC 2007
- TARS 2016
- Country
- ROIC United States
- TARS United States
- Employees
- ROIC N/A
- TARS N/A
- Industry
- ROIC Real Estate Investment Trusts
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ROIC Real Estate
- TARS Health Care
- Exchange
- ROIC Nasdaq
- TARS Nasdaq
- Market Cap
- ROIC 2.2B
- TARS 1.8B
- IPO Year
- ROIC N/A
- TARS 2020
- Fundamental
- Price
- ROIC $17.46
- TARS $54.35
- Analyst Decision
- ROIC Hold
- TARS Strong Buy
- Analyst Count
- ROIC 6
- TARS 5
- Target Price
- ROIC $15.75
- TARS $54.20
- AVG Volume (30 Days)
- ROIC 1.0M
- TARS 469.2K
- Earning Date
- ROIC 10-22-2024
- TARS 11-13-2024
- Dividend Yield
- ROIC 3.44%
- TARS N/A
- EPS Growth
- ROIC 57.91
- TARS N/A
- EPS
- ROIC 0.46
- TARS N/A
- Revenue
- ROIC $336,785,000.00
- TARS $129,621,000.00
- Revenue This Year
- ROIC N/A
- TARS $895.24
- Revenue Next Year
- ROIC $0.97
- TARS $73.78
- P/E Ratio
- ROIC $38.07
- TARS N/A
- Revenue Growth
- ROIC 4.18
- TARS 801.96
- 52 Week Low
- ROIC $11.87
- TARS $18.84
- 52 Week High
- ROIC $17.52
- TARS $54.44
- Technical
- Relative Strength Index (RSI)
- ROIC 70.92
- TARS 66.99
- Support Level
- ROIC $17.44
- TARS $51.08
- Resistance Level
- ROIC $17.48
- TARS $53.85
- Average True Range (ATR)
- ROIC 0.04
- TARS 2.41
- MACD
- ROIC -0.05
- TARS -0.05
- Stochastic Oscillator
- ROIC 50.00
- TARS 90.70
About ROIC Retail Opportunity Investments Corp. (MD)
Retail Opportunity Investments Corp is a self-managed real estate investment trust. The company specializes in the acquisition, ownership and management of necessity-based community and neighborhood shopping centers on the west coast of the United States, anchored by supermarkets and drugstores. The Company's primary business is the ownership, management, and redevelopment of retail real estate properties.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.